Holen Sie sich die Stockscreener-App
127.57
25.90%
26.22
Blueprint Medicines Corp Aktie (BPMC) Neueste Nachrichten
JPMorgan downgrades Blueprint Medicines stock after Sanofi acquisition - Investing.com
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines - GlobeNewswire
Sanofi to acquire Blueprint for up to $9.5B - BioPharma Dive
Blueprint Medicines (BPMC) Downgraded Following Sanofi's Acquisition Plans | BPMC Stock News - GuruFocus
Sanofi to acquire Blueprint Medicines, Boeing upgrade - Yahoo Finance
Sanofi to expand immunology offerings with Blueprint Medicines - Pharmaceutical Technology
Sanofi to fork out $9 million + to buy Blueprint Medicines - The Pharma Letter
Sanofi acquisition of Blueprint Medicines ‘sensible,’ says BofA - TipRanks
Sanofi buying Blueprint Medicines for up to $9.5 billion - Axios
Sanofi to Acquire Blueprint Medicines in Deal Valued at $9.5B - Contract Pharma
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines - Zacks Investment Research
Blueprint Medicines downgraded to Sector Perform from Outperform at Scotiabank - TipRanks
Weil-Led Sanofi To Buy US Drugmaker For Up To $9.5B - Law360
Blueprint Medicines (BPMC) Downgraded Following Sanofi Acquisition Plans | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Explodes Over 26%: Is This Biotech Stock Just Getting Started? - Daily Chhattisgarh News
Sanofi to Acquire Blueprint Medicines for Up to $9.5B - Genetic Engineering and Biotechnology News
Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. - Barron's
Cleveland-Cliffs, Tesla, Blueprint Medicines, Moderna, BioNTech, DraftKings, and More Movers - Barron's
Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Blueprint Medicines (BPMC) Receives Downgrade with Raised Price Target | BPMC Stock News - GuruFocus
BPMC: Needham Downgrades Blueprint Medicines to Hold, Price Targ - GuruFocus
Blueprint Medicines stock soars on Sanofi acquisition deal By Investing.com - Investing.com Canada
Blueprint Medicines (BPMC) Downgraded by Needham Following Sanofi Acquisition Plans | BPMC Stock News - GuruFocus
Sanofi to buy Blueprint Medicines in deal worth more than $9 billion - The Boston Globe
Citi maintains sell rating on Blueprint Medicines stock amid Sanofi deal - Investing.com
Analyst Expectations For Blueprint Medicines's Future - Nasdaq
Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover - Investopedia
Sanofi to buy Blueprint Medicines for $9.1B - The Business Journals
Morning Brew: Sanofi's $9.1B Acquisition of Blueprint Medicines - GuruFocus
Sanofi to buy US biopharma group Blueprint for up to $9.5 billion - Reuters
Blueprint Medicines CorpSanofi To Pay $500 Mln To Co If Deal Is Terminated Under Certain Circumstances - marketscreener.com
Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Blueprint Medicines (BPMC) Downgraded by Wedbush After Sanofi Acquisition Plan | BPMC Stock News - GuruFocus
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Yahoo Finance
Sanofi's Acquisition of Blueprint Medicines (BPMC) Deemed Pragmatic by Analyst | BPMC Stock News - GuruFocus
Moderna, Blueprint Medicines, Boeing - TradingView
French pharma firm Sanofi to acquire US-based Blueprint Medicines for $9.1B - Anadolu Ajansı
S&P 500 Futures Decline in Premarket Trading; Blueprint Medicines, Steel Dynamics Lead - Barron's
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket - Benzinga
Sanofi to buy US biopharma group Blueprint Medicines for $9.1 Billion equity value - Hindustan Times
Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B - Endpoints News
BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders - New Castle News
Blueprint Medicines Stock Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key. - Barron's
Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion - MSN
Blueprint Medicines Announces Merger Agreement with Sanofi - TipRanks
Sanofi to Acquire Blueprint Medicines for $9.5 Billion, Expanding Rare Disease Portfolio - TipRanks
Sanofi to Acquire Blueprint Medicines (BPMC) in $9.1 Billion Dea - GuruFocus
Sanofi to Acquire Blueprint Medicines (BPMC) for $129 Per Share | BPMC Stock News - GuruFocus
Sanofi to Buy US-based Blueprint Medicines in Boost for Rare Disease, Immunology Portfolios - marketscreener.com
These Stocks Are Moving the Most Today: Cleveland-Cliffs, Steel Dynamics, Tesla, NIO, Blueprint Medicines, and More - MSN
Cleveland-Cliffs, Steel Dynamics, Tesla, NIO, Blueprint Medicines, and More Market Movers - Barron's
Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline - WSJ
Sanofi Buys Blueprint Medicines In A $9.5 Billion Deal - Finimize
Sanofi draws up $9.1bn plan to buy Blueprint Meds - Pharmaphorum
M&A News: Sanofi Expands Cancer Drug Portfolio with $9.1B Blueprint Medicines Acquisition - TipRanks
Sanofi agreed to acquire Blueprint Medicines Corporation for $8.72 billion. - marketscreener.com
Sanofi to acquire Blueprint Medicines in $9.5 billion deal to bolster immunology push - domain-b.com
French pharma firm Sanofi in $9.5bn plan to buy Blueprint Medicines - Yahoo Finance
France: Sanofi to acquire Blueprint for up to US$9.5bn - Investors in Healthcare
Transcript : Blueprint Medicines Corporation, SanofiM&A Call - marketscreener.com
Market news - investments.halifax.co.uk
Sanofi to buy US biopharmaceutical firm Blueprint Medicines for $9.1bn - Sharecast.com
Sanofi (SNY) to Acquire Blueprint Medicines for $9.1 Billion - GuruFocus
Sanofi to acquire Blueprint Medicines for $9.1 billion - breakingthenews.net
Sanofi buys biopharma group Blueprint Medicines for $9.1B (NASDAQ:BPMC) - Seeking Alpha
Sanofi buys US biopharma group Blueprint in $9.1 billion deal - The Economic Times
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology | BPMC Stock News - GuruFocus
Sanofi to buy Blueprint Medicines for $9.1 bln - Investing.com Australia
1.76%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):